Japanese Journal of Clinical Oncology, Vol 28, Issue 11 688-695, Copyright © 1998 by Foundation for Promotion of Cancer Research
T Igarashi, S Shimizu, K Morishita, T Ohtsu, K Itoh, H Minami, H Fujii, Y Sasaki and K Mukai
A 42-year-old female with a mediastinal tumor and massive pleural effusion
ws admitted to our hospital in June 1993. Biopsy revealed lymphoblastic
lymphoma. She had no evidence of distant metastasis except pleural
effusion. Bone marrow examination revealed a normal karyotype (46, XY). The
patient had been progression-free for more than 1 year after achieving
complete remission by induction, consolidation and maintenance therapy
according to the standard chemotherapy and involved-field radiation for
lymphoblastic lymphoma. From May 1996 progressive leukopenia and
thrombocytopenia developed. The diagnosis of refractory anemia with excess
of blasts (RAEB) was made. Subsequently, in November 1996, she developed
acute myelogenous leukemia (AML), M4 type by FAB classification. The
karyotype of MDS and AML clones involved inversion (3) (q21q26) and
monosomy 7. The EVI 1 gene was examined and was proved to be rearranged and
activated. This may be the first case among the therapy-related cases of
MDS/AML reported whose karyotypes were followed and in which the mRNA
expression of EVI 1 gene involved was directly proved in the leukemogenesis
process of chemotherapy-induced secondary MDS and AML.
ORIGINAL ARTICLE
Acute myelogenous leukemia with monosomy 7, inv(3) (q21q26), involving activated EVI 1 gene occurring after a complete remission of lymphoblastic lymphoma: a case report
Department of Medicine, National Cancer Center Hospital East, Chiba, Japan. tigarash@east.ncc.go.jp
![]()
CiteULike
Connotea
Del.icio.us What's this?